Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition

Psychopharmacology

Volumn 180, Issue 2, 2005, Pages 366-376

  Tenn, Catherine C ^a   Kapur, Shitij ^a,b   Fletcher, Paul J ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Amphetamine; Latent inhibition; Phencyclidine; Prepulse inhibition; Schizophrenia; Sensitization

Indexed keywords

AMPHETAMINE; PHENCYCLIDINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; BRAIN DISEASE; BRAIN FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; LATENT INHIBITION; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSITIZATION; TIME SERIES ANALYSIS; WITHDRAWAL SYNDROME;

AMPHETAMINE; ANIMALS; AVOIDANCE LEARNING; CONDITIONING (PSYCHOLOGY); MALE; MENTAL PROCESSES; MOTOR ACTIVITY; NEURAL INHIBITION; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; STARTLE REACTION; TASTE;

EID: 21344448829     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2253-z     Document Type: Article

References (51)

1. Abi-Dargham A, Moore H (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9:404-416
2. Akiyama K, Kanzaki A, Tsuchida K, Ujike H (1994) Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schizophr Res 12:251-257
3. Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277-283
4. Baruch I, Hemsley DR, Gray JA (1988) Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598-606
5. Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215
6. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of propulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258
7. Carlsson M, Carlsson A (1990) Interaction between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276
8. Castner SA, Goldman-Rakic PS (2003) Amphetamine sensitization of hallucinatory-like behaviours is dependent on prefrontal cortex in nonhuman primates. Biol Psychiatry 54:105-110
9. Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241-253
10. Druhan JP, Geyer MA, Valentino RJ (1998) Lack of sensitization to the effects of d-amphetamine and apormorphine on sensorimotor gating in rats. Psychopharmacology 135:296-304
11. Ellenbroek BA, Knobbout DA, Cools AR (1997) The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Psychopharmacology (Berl) 129:112-120
12. Escobar M, Oberling P, Miller RR (2002) Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia. Neurosci Biobehav Rev 26:203-216
13. Greenberg BD, Segal DS (1985) Acute and chronic behavioural interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol Biochem Behav 23:99-105
14. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of model of schizophrenia. Am J Psychiatry 148:1301-1308
15. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
16. Jentsch JD, Elsworth JD, Redmond DE Jr, Roth RH (1997) Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J Neurosci 17:1769-1775
17. Jentsch JD, Taylor JR, Roth RH (1998a) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19:105-113
18. Jentsch JD, Tran A, Taylor JR, Roth RH (1998b) Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioural and neurochemical evidence. Psychopharmacology (Berl) 138:89-95
19. Johnson KM, Phillips M, Wang C, Kevetter GA (1998) Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52:709-722
20. Kolta MG, Shreve P, De Souza V, Uretsky NJ (1985) Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine. Neuropharmacology 24:823-829
21. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6:869-872
22. Laruelle M (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 31:371-384
23. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine and schizophrenia. Ann N Y Acad Sci 1003:138-158
24. Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205-229
25. Lubow RE (1997) Latent inhibition as a measure of learned inattention: some problems and solutions. Behav Brain Res 88:75-83
26. Martinez ZA, Ellison GD, Geyer MA, Swerdlow NR (1999) Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology 21:28-39
27. Murphy CA, Di Iorio L, Feldon J (2001a) Effects of psychostimulant withdrawal on latent inhibition of conditioned active avoidance and prepulse inhibition of the acoustic startle response. Psychopharmacology (Berl) 156:155-164
28. Murphy CA, Fend M, Russig H, Feldon J (2001b) Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine. Behav Neurosci 115:1247-1256
29. Nelson LR, Ellison G (1978) Enhanced stereotypies after repeated injections but not continuous amphetamines. Neuropharmacology 17:1081-1084
30. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 49:975-982
31. Phillips M, Wang C, Johnson KM (2001) Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296:905-913
32. Post RM (1980) Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci 26:1275-1282
33. Robinson TE (1984) Behavioural sensitization: characterization of enduring changes in rotational behaviour produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology (Berl) 84:466-475
34. Robinson TE, Becker JB (1986) Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198
35. Russig H, Murphy CA, Feldon J (2002) Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26:765-777
36. Sato M, Numachi Y, Hamamura T (1992) Relapse of paranoid psychotic state in methamphetamine model in schizophrenia. Schizophr Bull 18:115-122
37. Scalzo FM, Holson RR (1992) The ontogeny of behavioural sensitization to phencyclidine. Neurotoxicol Teratol 14:7-14
38. Schroeder U, Schroeder H, Darius J, Grecksch G, Sabel BA (1998) Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav Brain Res 97:59-68
39. Schulz B, Fendt M, Pedersen V, Koch M (2001) Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine. Psychopharmacology (Berl) 156:177-181
40. Solomon PR, Staton DM (1982) Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Biol Psychiatry 17:743-756
41. Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981) Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biol Psychiatry 16:519-537
42. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M (2003) Psychotic symptoms in methamphetamine psychotic inpatients. Int J Neuropsychopharmacol 6:347-352
43. Tenn CC, Fletcher PJ, Kapur S (2003) Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64:103-114
44. Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179
45. Turgeon SM, Case LC (2001) The effects of phencyclidine pre-treatment on amphetamine-induced behaviour and c-Fos expression in the rat. Brain Res 888:302-305
46. Ujike H (2002) Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 4:177-184
47. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology (Berl) 114:657-664
48. Weiner I (2003) The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl) 169:257-297
49. Weiner I, Feldon J (1992) Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmacol Biochem Behav 42:625-631
50. Weiner I, Lubow RE, Feldon J (1988) Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871-878
51. Xu X, Domino EF (1994) Phencyclidine-induced behavioural sensitization. Pharmacol Biochem Behav 47:603-608